ACS Journal Cancer shared a post on X, about a recent paper by Mutlay Sayan et al. published in Cancer Journal:

“This new study from Dana-Farber’s Radiation Oncology researchers validates that a PSA level >0.5 ng/mL after neoadjuvant ADT and before RT is prognostic and significantly associated with an increased ACM risk.”

“Biochemical response to neoadjuvant androgen deprivation therapy before radiation therapy and the risk of death in patients with unfavorable-risk prostate cancer: A secondary analysis of a randomized clinical trial”

Authors: Mutlay Sayan, Ming-Hui Chen, Jing Wu, Jonathan Leeman, Shalini Moningi, Martin King, Peter Orio, Paul Nguyen, Anthony D’Amico.

Biochemical Response to ADT and Mortality Risk in Prostate Cancer - ACS Journal Cancer

More posts featuring ACS Journal Cancer.

Biochemical Response to ADT and Mortality Risk in Prostate Cancer – ACS Journal Cancer